Did you know?

**AreNA PHARmACEUTICALS**

Arena Pharmaceuticals is a clinical stage biopharmaceutical company with assets across multiple therapeutic areas including gastrointestinalology, cardiology, and dermatology. Arena is driven to deliver novel, transformational medicines with optimized pharmacology to fulfill global unmet needs. We strive to improve lives for those who suffer from disease by utilizing the best employees who are passionate about Arena’s shared responsibility to our patients and each other. To learn more about Arena, please visit us at www.arenapharm.com.

**BOSLEY**

Bosley provides surgical, having performed more than 300,000 hair transplantation procedures, and medical hair restoration solutions as well as scalp micropigmentation. The company was founded in 1974 and is based in Beverly Hills, California and has surgical offices and consultation offices across the United States. Bosley is a longtime supporter of hair research and the American Hair Research Society and is the founding supporter of its Mentorship Program. More information may be found at: www.bosley.com

**Cassiopea**

Cassiopea completed Phase 2 clinical trials in 2019 for Clascoterone solution, a novel topical anti-androgen, for the treatment of male androgenetic alopecia (AGA) and began a Phase 2 AGA trial in females; a Phase 3 male AGA trial is expected to begin in 2020. The NDA for Clascoterone 1% cream, a novel topical anti-androgen, for the treatment of acne, was filed in 2019. Cassiopea is a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. Our initial focus is on the topical treatment of acne; androgenetic alopecia, and genital warts. Additional information on our research may be found at www.cassiopea.com.

**CoNCERT Pharmaceuticals Inc.**

Concert is committed to bringing a new treatment option to patients with alopecia areata. At Concert we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative medicines that positively impact patients and address important medical needs. CTP-543, a novel, oral Janus kinase inhibitor for the treatment of alopecia areata, has been granted Fast Track status by the FDA. Concert intends to advance CTP-543 into Phase 3 evaluation in patients with moderate-to-severe alopecia areata in 2020. To learn more about our clinical trials please visit www.concertpharma.com or www.clinicaltrials.gov.

**NUTRAFOL**

Dedicated to the science of hair wellness, Nutrafol’s team of doctors and researchers sought out scientific advancements at the forefront of genetics, biotechnology, and anti-aging medicine to create the next generation of physician-formulated hair health innovation. Nutrafol is trusted by over 1,500 top doctors for its integrative approach firmly rooted in pioneering nutraceutical science—with highly-concentrated natural products clinically shown to improve hair growth performance. The results speak for themselves: in a 6-month, randomized, double-blind, placebo-controlled study, Nutrafol Women users showed a 10.3% improvement in terminal hairs, while placebo users showed a 3.5% improvement. For additional information on hair wellness and Nutrafol’s customized solution for all your hair needs, visit www.nutrafol.com.

**samumed**

Samumed, LLC is a pharmaceutical platform company that has made important advances in the biology of tissue regeneration through the discovery of novel targets in the Wnt pathway, an essential driver of tissue health. Samumed is currently conducting early- to advanced-stage clinical trials with several potential disease-modifying drug candidates. Samumed’s current clinical trials cover a range of prevalent diseases with high unmet therapeutic need, including osteoarthritis, oncology, Alzheimer’s disease, idiopathic pulmonary fibrosis, tendinopathy, and androgenetic alopecia.

Samumed’s compound, SM04554, is a topical, small-molecule Wnt pathway activator in development for the treatment of androgenetic alopecia. It is in a Phase 2/3 trial conducted as a pivotal study in Turkey and is under an IND with the FDA. Additional information on Samumed’s research may be found by visiting www.samumed.com.

**Viviscal PRO**

Advanced Hair Health

The efficacy of Viviscal is supported in ten published clinical studies, including the most recent double-blind, placebo-controlled scientific research program which was designed exclusively to study women’s hair growth supplements. The study demonstrated a statistically significant reduction in hair shedding, increase in hair thickness and increase in terminal hair count over a six-month period. Additional information and a full overview of the clinical trials can be found at: https://www.viviscalprofessional.com/clinically-proven-studies
The NAHRS Seal of Recognition Program was created to inform physicians and consumers about products whose quality and effectiveness are beneficial in some aspect in promoting healthy hair or scalp, in diagnosing or treating hair or scalp disease, in diagnosing or treating hair loss, or in stimulating or inhibiting hair growth.

Seal Product Directory

**HairMax LaserComb** - The HairMax LaserComb is available in 3 models and has been clinically proven to increase hair counts in men and women with androgenetic alopecia.

**Nioxin DiaMax with HTX™**, is proven to increase the thickness of each existing hair strand.

**Keranique Lift & Repair Treatment Spray** - “for anti-frizz, protection from heat damage, strengthens the hair fiber, and diffusion into the cuticle”

**Pantene Pro-V Daily Thickening Treatment** - "Pantene's Daily Thickening Treatment thickens individual hair fibers."

**Pantene Pro-V Medium-Thick, 4-product regimen** - “long lasting smoothness,” with “long lasting” defined as >24 hours

The AHRS is grateful to the corporate sponsors who support its meetings, programs, and overall organization. They support hair research and advancing the field and are involved in various aspects from hair loss and hair growth, hair care, and hair transplantation.

The information in this handout is current as of April 8, 2020